Cumarine of DOAC bij kwetsbare ouderen met atriumfibrilleren?

Translated title of the contribution: Coumarin or DOAC in frail elderly patients with atrial fibrillation?

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

OBJECTIVE: To investigate whether frail elderly people with atrial fibrillation (AF) who are currently using a vitamin K antagonist (VKA) should be switched to a direct-acting oral anticoagulant (DOAC). DESIGN: Randomized clinical trial. METHODS: 662 frail elderly AF patients were switched to a DOAC, and 661 patients continued their VKA. The primary endpoint was a major or clinically relevant non-major bleeding during 1 year of follow-up. Secondary endpoints included thrombo-embolic events. RESULTS: The mean age of the included patients was 83 years. In the 'switch to DOAC arm', 101 bleeding events (15.3%) occurred and in the 'continue with VKA arm', 62 bleeding events (9.4%); an increase of 69% more bleeding events (P-value 0.001). The number of thrombo-embolic events was not significantly different between both groups. CONCLUSION: Switching from a VKA to a DOAC in frail elderly people with AF leads to 69% more bleeding, without a difference in thrombo-embolic events.

Translated title of the contributionCoumarin or DOAC in frail elderly patients with atrial fibrillation?
Original languageDutch
Article numberD8026
JournalNederlands Tijdschrift voor Geneeskunde
Volume168
Publication statusPublished - 29 Jan 2024

Keywords

  • Humans
  • Aged
  • Aged, 80 and over
  • Atrial Fibrillation/complications
  • Frail Elderly
  • Vitamin K
  • Administration, Oral
  • Anticoagulants/adverse effects
  • Hemorrhage/chemically induced
  • Coumarins/therapeutic use
  • Stroke/complications

Fingerprint

Dive into the research topics of 'Coumarin or DOAC in frail elderly patients with atrial fibrillation?'. Together they form a unique fingerprint.

Cite this